It has been shown that hypermethylation of SEPT9 promoter regions was detected in tumor tissue and plasma of CRC patients, which was proposed to be a sensitive and specific biomarker for non‐invasive CRC screening.[56, 57, 58] Thus, SEPT9 was once regarded as a tumor suppressor. The gene discussed is SEPTIN9; the disease is neoplasm.